Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM1P6FR)

Drug Name
ARRY-162 Drug Info
Synonyms
606143-89-9; Binimetinib; MEK162; MEK-162; ARRY-438162; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; ARRY 162; UNII-181R97MR71; Binimetinib (MEK162, ARRY-162, ARRY-438162); 181R97MR71; MEK162 (ARRY-162, ARRY-438162); 6-(4-bromo-2-fluorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; Binimetinib [USAN:INN]; MEK 162; ARRY 438162; MEK162(Binimetinib); Binimetinib (JAN/USAN); D0C4LF; NVP-ME
Cross-matching ID
PubChem CID
10288191
ChEBI ID
CHEMBL3187723
CAS Number
CAS 606143-89-9
TTD Drug ID
D0C4LF
VARIDT Drug ID
DR01336
INTEDE Drug ID
DR0214
ACDINA Drug ID
D00883

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Oxidative phosphorylation 2.06 0.00e+0 93/133 (69.92%) COX5B;LHPP;COX7B;...
Allograft rejection 2.05 0.00e+0 32/38 (84.21%) HLA-B;HLA-F;HLA-DRB1;...
Butanoate metabolism 2.04 0.00e+0 23/28 (82.14%) HMGCS1;BDH2;ALDH5A1;...
Graft-versus-host disease 2.03 0.00e+0 32/42 (76.19%) HLA-B;HLA-F;HLA-DRB1;...
Metabolism of xenobiotics by cytochrome P450 2.03 0.00e+0 49/77 (63.64%) GSTP1;ALDH3A1;GSTK1;...
Lysosome 2.01 0.00e+0 115/128 (89.84%) NEU1;CTSA;LITAF;...
Glycosaminoglycan degradation 1.94 3.62e-3 19/19 (100%) GLB1;HGSNAT;GALNS;...
Cardiac muscle contraction 1.92 3.16e-3 64/87 (73.56%) TNNC1;TPM2;TPM1;...
Herpes simplex virus 1 infection 1.92 2.81e-3 165/498 (33.13%) IRF9;NFKBIA;TAP1;...
Influenza A 1.88 2.53e-3 156/172 (90.7%) MX1;IRF9;TNFSF10;...
Type I diabetes mellitus 1.87 3.45e-3 38/43 (88.37%) HLA-B;HLA-F;HLA-DRB1;...
Hepatitis C 1.84 4.22e-3 139/157 (88.54%) MX1;IFIT1;IRF9;...
Sulfur metabolism 1.83 4.87e-3 9/10 (90%) SELENBP1;TST;MPST;...
Steroid biosynthesis 1.82 4.52e-3 19/20 (95%) MSMO1;TM7SF2;LSS;...
Antigen processing and presentation 1.81 5.91e-3 60/78 (76.92%) TAP1;HLA-B;HLA-F;...
Staphylococcus aureus infection 1.80 5.54e-3 72/95 (75.79%) CFB;KRT19;KRT13;...
Other glycan degradation 1.76 1.04e-2 13/18 (72.22%) NEU1;MAN2B2;GLB1;...
NOD-like receptor signaling pathway 1.75 1.05e-2 145/181 (80.11%) IRF9;NFKBIA;TXNIP;...
Inflammatory bowel disease 1.74 1.20e-2 58/65 (89.23%) HLA-DRB1;STAT6;HLA-DRA;...
Synthesis and degradation of ketone bodies 1.74 1.20e-2 9/10 (90%) HMGCS1;BDH2;HMGCL;...
Mitophagy 1.73 1.27e-2 56/68 (82.35%) OPTN;FOXO3;TP53;...
Autoimmune thyroid disease 1.73 1.38e-2 46/53 (86.79%) HLA-B;HLA-F;HLA-DRB1;...
Necroptosis 1.65 3.36e-2 113/159 (71.07%) CAPN1;IRF9;TNFSF10;...
Phagosome 1.63 4.22e-2 118/152 (77.63%) TAP1;HLA-B;ITGAV;...
Cell adhesion molecules 1.62 4.15e-2 118/148 (79.73%) ALCAM;VTCN1;HLA-B;...
Shigellosis 1.62 4.33e-2 180/246 (73.17%) CAPN1;NFKBIA;MYL9;...
Sphingolipid metabolism 1.61 4.69e-2 32/49 (65.31%) NEU1;PSAP;PLPP2;...
Measles 1.61 4.56e-2 133/139 (95.68%) MX1;IRF9;NFKBIA;...
Hypertrophic cardiomyopathy 1.60 4.67e-2 81/90 (90%) TNNC1;TPM2;ITGAV;...
Coronavirus disease 1.59 4.94e-2 215/232 (92.67%) CFB;ISG15;MX1;...
Cysteine and methionine metabolism -1.62 2.71e-2 43/50 (86%) MTAP;GOT1;BCAT1;...
Glycine, serine and threonine metabolism -1.62 2.69e-2 31/40 (77.5%) SRR;GLDC;PSPH;...
Base excision repair -1.67 1.61e-2 29/33 (87.88%) POLB;POLE;PARP1;...
Oocyte meiosis -1.71 1.25e-2 90/129 (69.77%) PPP2R5D;CPEB1;CAMK2A;...
mRNA surveillance pathway -1.77 7.67e-3 71/98 (72.45%) PPP1CC;PPP2R2A;PELO;...
Pyrimidine metabolism -1.77 8.18e-3 40/56 (71.43%) TK1;RRM1;CANT1;...
Non-homologous end-joining -1.81 5.54e-3 11/13 (84.62%) DCLRE1C;XRCC5;DNTT;...
One carbon pool by folate -1.85 3.48e-3 15/20 (75%) MTHFD2L;TYMS;GART;...
Homologous recombination -1.87 3.23e-3 35/41 (85.37%) BARD1;TOP3A;MRE11;...
Basal transcription factors -1.88 2.35e-3 37/45 (82.22%) ERCC2;GTF2E2;GTF2I;...
Progesterone-mediated oocyte maturation -1.91 1.94e-3 75/100 (75%) RPS6KA2;MAPK8;RAF1;...
RNA polymerase -1.92 2.15e-3 23/31 (74.19%) POLR3C;POLR2E;POLR2I;...
Nucleotide excision repair -1.99 0.00e+0 40/47 (85.11%) GTF2H4;CDK7;GTF2H1;...
Fanconi anemia pathway -2.15 0.00e+0 36/54 (66.67%) FANCC;BRCA2;FANCE;...
Spliceosome -2.19 0.00e+0 101/150 (67.33%) PPIH;HNRNPC;CDC5L;...
Cell cycle -2.31 0.00e+0 110/124 (88.71%) CDKN2C;ANAPC1;PKMYT1;...
Mismatch repair -2.32 0.00e+0 22/23 (95.65%) RFC1;RPA3;MSH6;...
RNA transport -2.38 0.00e+0 128/186 (68.82%) AAAS;NUP214;SEC13;...
Ribosome biogenesis in eukaryotes -2.51 0.00e+0 52/108 (48.15%) FCF1;RIOK2;DROSHA;...
DNA replication -2.51 0.00e+0 34/36 (94.44%) RFC1;RPA3;RNASEH1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.04uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 10uM 24H